MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$480,999K
Net Income
$229,913K
Net Profit Margin
47.80%
EPS
$1.9
Unit: Thousand (K) dollars
Revenue Breakdown
Royalty
Bulk RHu PH20
Proprietary Products Sales
Others
Revenue Breakdown
Royalty
Revenue From Contract With Custo...
Collaborative Agreements
Revenue Breakdown
Royalty
Bulk RHu PH20
Proprietary Products Sales
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
480,999
376,708
451,767
354,264
Cost of sales
79,171
79,238
78,770
55,242
Amortization of intangibles
29,512
29,512
23,376
17,762
Research and development
27,664
25,560
31,897
17,251
Selling, general and administrative
56,998
57,881
77,028
46,088
Impairment of intangible asset
-
-
12,175*
-
Acquired in-process research and development expense
-
-
321,412*
-
Total operating expenses
193,345
192,191
544,658
136,343
Operating income
287,654
184,517
-92,891
217,921
Investment and other income, net
2,836
1,318
2,430
5,333
Inducement expense related to convertible notes
-
-
5,477*
-
Contingent liability fair value measurement gain
-
-
0*
-
Interest expense
5,588
5,508
4,911
4,296
Income before income tax expense
284,902
180,327
-100,849
218,958
Income tax expense
54,989
30,278
40,742
43,733
Net income
229,913
150,049
-141,591
175,225
Basic EPS
1.96
1.27
-1.204
1.49
Diluted EPS
1.9
1.22
-1.156
1.43
Basic Average Shares
117,274,000
118,144,000
117,583,000
117,219,000
Diluted Average Shares
121,215,000
122,875,000
122,483,000
122,331,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
Bulk RHu PH20
$59,618K
Proprietary Products Sales
$55,428K
(19.32%↑ Y/Y)
Device Partnered
Products
$14,580K
(23.70%↑ Y/Y)
Upfront Fees
$35,500K
Event Based
Development And Regulatory...
$5,706K
(-76.71%↓ Y/Y)
Device Licensing And
Development
$2,468K
(-39.36%↓ Y/Y)
Royalty
$307,699K
(49.63%↑ Y/Y)
Product
$129,626K
(59.03%↑ Y/Y)
Collaborative Agreements
$43,674K
(13.23%↑ Y/Y)
Total revenues
$480,999K
(47.67%↑ Y/Y)
Operating income
$287,654K
(42.09%↑ Y/Y)
Investment and other
income, net
$2,836K
(-58.84%↓ Y/Y)
Total operating
expenses
$193,345K
(56.84%↑ Y/Y)
Income before income
tax expense
$284,902K
(39.02%↑ Y/Y)
Interest expense
$5,588K
(27.17%↑ Y/Y)
Cost of sales
$79,171K
(70.78%↑ Y/Y)
Selling, general and
administrative
$56,998K
(36.97%↑ Y/Y)
Amortization of intangibles
$29,512K
(66.15%↑ Y/Y)
Research and development
$27,664K
(57.69%↑ Y/Y)
Net income
$229,913K
(39.21%↑ Y/Y)
Income tax expense
$54,989K
(38.24%↑ Y/Y)
Buy us a coffee
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)